What is BMY's current stock price?

As of now, BMY is trading at $50.24, with a daily change of +4.12%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

BMY Stock Analysis & IQ Rating | Bristol-Myers Squibb

BMY

Bristol-Myers Squibb

$50.24

+$1.99 | +4.12%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$63.33

MKT CAP

$102.50B

52W Low

$42.52

VOL

$8.30M

P/E Ratio

16.96

AVG VOL

$15.71M

RSI

65.88

TREND

Uptrend

BMY Stock IQ

Login to see Bristol-Myers Squibb (BMY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

BMY Target Price

Login to display

Strengths

BMY Rewards

Earnings are forecast to grow

BMY Rewards

Trading below its fair value

BMY Rewards

Investors confidence is positive

Technical Indicators

BMY Technical Indicators

5+ Days Up

BMY Price Performance

$46.47 (+8.11%)

$47.23 (+6.37%)

$47.44 (+5.90%)

$55.87 (-10.08%)

1year

6month

3month

1month

BMY Risk Level

BMY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

BMY Analysts Opinion

BMY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

BMY Analysts Opinion

BMY Analysts opinion is negative and it remained unchanged from the past 3 months

BMY Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

75%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

NA

100%

BMY Street Sentiment

BMY Street Sentiment is extremely bullish and have positive views on the near-term outlook

BMY Performance Sentiment

Sentiments overview associated with BMY events and the stock performance.

75%

0%

Positive

Negative

9 out of 12
events present

0 out of 12
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$49.25

Resistance
Price

$43.41

Current Price Range

$49.73

Show methods +

Linked to BMY

IQ

Close Price

Change

JNJ

4.09

205.83

+0.21%

BMY Latest Analysis +

Goldman Sachs Maintains Bristol-Myers Squibb (BMY) Neutral Recommendation. Fintel reports that on December 2 2025 Goldman Sachs maintained coverage of Bristol-Myers Squibb (NYSE:BMY) with a Neutral recommendation. Analyst Price Forecast Suggests 7.81% Upside

Today

$50.24 | +4.12%

Potential

Rating

Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates. Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data according to the firm offers tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis which bolsters trust in BMYS [….]

Today

$50.24 | +4.12%

Rating

Heres Why Bristol Myers Squibb (BMY) is a Strong Value Stock. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Mon Dec 1, 2025

$49.18 | -0.04%

Potential

Bristol Myers Squibb Unveils Positive Trial Data In Hematology Pipeline . (RTTNews) - Drug maker Bristol Myers Squibb Co. (BMY) announced Monday positive and promising data from the trials in Hematology pipeline comprising Iberdomide Golcadomide BCL6 Degrader as well as Breyanzi.

Mon Dec 1, 2025

$49.18 | -0.04%

Activity

Bristol Myers Squibb Gets European Commission Approval To Expand Use Of Breyanzi In MCL . (RTTNews) - Bristol Myers Squibb (BMY) on Tuesday announced that it has received approval from the European Commission to expand the use of its CAR T cell therapy Breyanzi for relapsed or refractory mantle cell lymphoma. The approval applies to all European Union member states

Tue Nov 25, 2025

$49.05 | +2.70%

Activity

Bristol Myers Squibb J&J Discontinue Phase 3 Librexia ACS Study Of Milvexian After Interim Review . (RTTNews) - Bristol-Myers Squibb Co. (BMY) on Friday said it has halted the Phase 3 Librexia ACS trial of milvexian conducted in partnership with Johnson & Johnson (JNJ) in patients who recently experienced an acute coronary syndrome (ACS) event.

Fri Nov 14, 2025

$46.65 | -4.09%

Activity

Heres Why Bristol Myers Squibb (BMY) is a Strong Value Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Thu Nov 13, 2025

$48.63 | -0.91%

Potential

FAQ About BMY Stock Insights

What is BMY current stock price?

What are BMY stock strengths?

What is BMY Risk Level?

What is BMY market cap and volume?

What is BMY current Stock IQ?

Should I buy BMY stock right now?

Is BMY a Strong Buy right now?

What does a 'Strong Buy' rating mean for BMY?

What does a 'Strong Sell' rating mean for BMY?

What factors influence BMY's Stock IQ?

Explore our BMY Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored BMY Stock Strategies
Effective Risk Management

FIND US ON

Receive our BMY Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

BMY

Bristol-Myers Squibb

Current Price

$50.24

+$1.99 | +4.12%

52W High

$63.33

MKT CAP

$102.50B

52W Low

$42.52

VOL

$8.30M

P/E Ratio

16.96

AVG VOL

$15.71M

RSI

65.88

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

BMY Rewards

Earnings are forecast to grow

BMY Rewards

Trading below its fair value

BMY Rewards

Investors confidence is positive

Technical Indicators

BMY Technical Indicators

5+ Days Up

Linked to BMY

Symbol

IQ

Close

Change

JNJ

4.09

205.83

+0.21%

BMY Price Performance

$46.47 (+8.11%)

$47.23 (+6.37%)

$47.44 (+5.90%)

$55.87 (-10.08%)

1year

6month

3month

1month

BMY Analysts Opinion

BMY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

BMY Analysts Opinion

BMY Analysts opinion is negative and it remained unchanged from the past 3 months

BMY Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

75%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

NA

100%

BMY Street Sentiment

BMY Street Sentiment is extremely bullish and have positive views on the near-term outlook

BMY Risk Level

BMY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

BMY Performance Sentiment

Sentiments overview associated with BMY events and the stock performance.

75%

0%

Positive

Negative

9 out of 12
events present

0 out of 12
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$49.25

Resistance
Price

$43.41

Current Price Range

$49.73

Show methods +

BMY Stock IQ

Login to unlock Bristol-Myers Squibb (BMY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

BMY Latest Analysis

Goldman Sachs Maintains Bristol-Myers Squibb (BMY) Neutral Recommendation. Fintel reports that on December 2 2025 Goldman Sachs maintained coverage of Bristol-Myers Squibb (NYSE:BMY) with a Neutral recommendation. Analyst Price Forecast Suggests 7.81% Upside

Today

$50.24 | +4.12%

Potential

Rating

Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates. Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data according to the firm offers tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis which bolsters trust in BMYS [….]

Today

$50.24 | +4.12%

Rating

Heres Why Bristol Myers Squibb (BMY) is a Strong Value Stock. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Mon Dec 1, 2025

$49.18 | -0.04%

Potential

Bristol Myers Squibb Unveils Positive Trial Data In Hematology Pipeline . (RTTNews) - Drug maker Bristol Myers Squibb Co. (BMY) announced Monday positive and promising data from the trials in Hematology pipeline comprising Iberdomide Golcadomide BCL6 Degrader as well as Breyanzi.

Mon Dec 1, 2025

$49.18 | -0.04%

Activity

Bristol Myers Squibb Gets European Commission Approval To Expand Use Of Breyanzi In MCL . (RTTNews) - Bristol Myers Squibb (BMY) on Tuesday announced that it has received approval from the European Commission to expand the use of its CAR T cell therapy Breyanzi for relapsed or refractory mantle cell lymphoma. The approval applies to all European Union member states

Tue Nov 25, 2025

$49.05 | +2.70%

Activity

Bristol Myers Squibb J&J Discontinue Phase 3 Librexia ACS Study Of Milvexian After Interim Review . (RTTNews) - Bristol-Myers Squibb Co. (BMY) on Friday said it has halted the Phase 3 Librexia ACS trial of milvexian conducted in partnership with Johnson & Johnson (JNJ) in patients who recently experienced an acute coronary syndrome (ACS) event.

Fri Nov 14, 2025

$46.65 | -4.09%

Activity

Heres Why Bristol Myers Squibb (BMY) is a Strong Value Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Thu Nov 13, 2025

$48.63 | -0.91%

Potential

Discover BMY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of BMY. We're here to help you make informed investment decisions today.

FIND US ON

Receive our BMY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

BMY Stock trends

BMY Stock performance

BMY Stock analysis

BMY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BMY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BMY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

BMY Stock Analysis & IQ Rating | Bristol-Myers Squibb

BMY Stock IQ

BMY Target Price

BMY Risk Level

BMY Analysts Opinion

BMY Street Sentiment

BMY Performance Sentiment

Technical Price Levels

Explore our BMY Stock insights

Receive our BMY Daily Alerts

BMY Street Sentiment

BMY Risk Level

Technical Price Levels

Discover BMY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of BMY. We're here to help you make informed investment decisions today.

Receive our BMY Daily Alerts

BMY Runner Alarm